{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-24-000411","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.638053+00:00","generated_at":"2026-06-05T08:20:14.631450+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity","bullets":["NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.","Disclosed semaglutide as API in NPM-139, a once-yearly implant for chronic weight management.","Strategic shift to prioritize obesity implants; NPM-115 designed for twice-yearly dosing.","IND for NPM-119 (type 2 diabetes) on clinical hold; expects to submit CMC info to FDA in H1 2024.","Plans to submit IND for NPM-115 first-in-human obesity study later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-24-000411","json":"https://secwatch.observer/filing/0001753926-24-000411.json","markdown":"https://secwatch.observer/filing/0001753926-24-000411.md","text":"https://secwatch.observer/filing/0001753926-24-000411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/0001753926-24-000411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392624000411/g084078_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:20:14.631450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}